Fmr LLC Boosts Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Fmr LLC boosted its holdings in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) by 54,095.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 82,919 shares of the company’s stock after purchasing an additional 82,766 shares during the quarter. Fmr LLC owned about 0.29% of Aerovate Therapeutics worth $173,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of AVTE. GSA Capital Partners LLP increased its holdings in shares of Aerovate Therapeutics by 226.8% in the 3rd quarter. GSA Capital Partners LLP now owns 413,795 shares of the company’s stock worth $865,000 after buying an additional 287,163 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Aerovate Therapeutics in the second quarter worth about $53,000. Deerfield Management Company L.P. Series C bought a new stake in Aerovate Therapeutics during the second quarter worth approximately $2,343,000. Affinity Asset Advisors LLC bought a new stake in Aerovate Therapeutics during the second quarter worth approximately $332,000. Finally, XTX Topco Ltd purchased a new stake in Aerovate Therapeutics during the second quarter valued at approximately $35,000.

Aerovate Therapeutics Stock Performance

Shares of Aerovate Therapeutics stock opened at $2.53 on Friday. The stock has a market cap of $73.05 million, a price-to-earnings ratio of -0.85 and a beta of 1.01. The stock has a 50 day moving average price of $2.52 and a 200-day moving average price of $3.29. Aerovate Therapeutics, Inc. has a one year low of $1.25 and a one year high of $32.42.

Aerovate Therapeutics (NASDAQ:AVTE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.03. Sell-side analysts predict that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.